Publicacions en col·laboració amb investigadors/es de Eli Lilly and Company (5)

2023

  1. Which people with diabetes are treated with a disposable, half-unit insulin pen? A real-world, retrospective, database study in Spain

    Endocrinology, Diabetes and Metabolism, Vol. 6, Núm. 6

2021

  1. Conversations and Reactions Around Severe Hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers

    Endocrinologia, Diabetes y Nutricion, Vol. 68, Núm. 8, pp. 557-566

2017

  1. Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?

    International Journal of General Medicine, Vol. 10, pp. 23-26

2016

  1. Eficacia y seguridad de empagliflozina en combinación con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2

    Endocrinologia y Nutricion, Vol. 63, Núm. 10, pp. 519-526

2013

  1. Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. insulin glargine titrated to target in patients with Type2 diabetes: An open-label randomized trial

    Diabetic Medicine, Vol. 30, Núm. 1, pp. 109-113